Author

S. S. Lueong

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1 Approach:statistical model· 1

Frequent Co-Authors

D. Rauh· 2 shared J. T. Siveke· 2 shared A. A. Z. Tiofack· 1 shared A. J. Njouendou· 1 shared A. M. Winkelkotte· 1 shared A. Paschen· 1 shared A. Roesch· 1 shared A. Sechi· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Rauh

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis

A. J. Njouendou, A. A. Z. Tiofack, R. N. Kenfack, S. N. Ananga, E. H. M. D. Bell, G. Simo, J. D. Hoheisel, J. T. Siveke, S. S. Lueong

The paper identifies SOX2 amplification as a driver of tumor aggressiveness by sustaining inflammation through the FOSL2/IL6 axis, leading to DNA damage and genome instability.

bioRxiv · Jun 9, 2022 · PreprintCancer Biology

Persister state-directed transitioning and vulnerability in melanoma

H. Chauvistre, B. Shannan, S. M. Daignault, R. J. Ju, D. Picard, S. Egetemaier, R. Varaljai, A. Sechi, F. Kaschani, O. Keminer, S. J. Stehbens, Q. Liu, X. Yin, K. Jeyakumar, F. C. E. Vogel, , A. Roesch

This study identifies a compound that induces a persister state in melanoma cells, promoting differentiation and sensitizing them to a prodrug, offering a dual-target strategy for treatment.

Nature Communications · Jun 1, 2022Peer-reviewedCancer Biology

Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma

I. Heid, S. Karakaya, C. Muench, S. S. Lueong, A. M. Winkelkotte, S. T. Liffers, L. Godfrey, P. F. Cheung, K. Savvatakis, G. J. Topping, F. Englert, L. Kritzner, M. Grashei, T. Kunzke, N. Sun, , J. T. Siveke

This study identifies functional metabolic differences between PDAC subtypes and shows that non-invasive HP-MRS can detect glycolytic tumor metabolism.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology